$CING
Cingulate Inc.

2024 Q4 Form 10-Q Financial Statement

#000149315224043916 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.854M
YoY Change 1.29%
% of Gross Profit
Research & Development $1.429M
YoY Change -63.59%
% of Gross Profit
Depreciation & Amortization $165.4K
YoY Change 6.95%
% of Gross Profit
Operating Expenses $1.429M
YoY Change -63.59%
Operating Profit -$3.282M
YoY Change -42.92%
Interest Expense $50.48K
YoY Change -78.75%
% of Operating Profit
Other Income/Expense, Net $50.48K
YoY Change -122.01%
Pretax Income -$3.232M
YoY Change -45.95%
Income Tax
% Of Pretax Income
Net Earnings -$3.232M
YoY Change -45.95%
Net Earnings / Revenue
Basic Earnings Per Share -$1.83
Diluted Earnings Per Share -$1.83
COMMON SHARES
Basic Shares Outstanding 3.212M shares 950.5K shares
Diluted Shares Outstanding 1.766M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.04M
YoY Change 404.53%
Cash & Equivalents $10.00M
Short-Term Investments
Other Short-Term Assets $1.301M
YoY Change 42.99%
Inventory
Prepaid Expenses
Receivables $2.250K
Other Receivables $0.00
Total Short-Term Assets $11.34M
YoY Change 290.83%
LONG-TERM ASSETS
Property, Plant & Equipment $2.067M
YoY Change -18.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $2.236M
YoY Change -24.64%
TOTAL ASSETS
Total Short-Term Assets $11.34M
Total Long-Term Assets $2.236M
Total Assets $13.58M
YoY Change 131.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $906.2K
YoY Change -45.75%
Accrued Expenses $402.2K
YoY Change -41.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change -100.0%
Long-Term Debt Due $8.810K
YoY Change -55.95%
Total Short-Term Liabilities $1.543M
YoY Change -73.09%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.543M
Total Long-Term Liabilities
Total Liabilities $1.543M
YoY Change -74.15%
SHAREHOLDERS EQUITY
Retained Earnings -$102.4M
YoY Change 19.06%
Common Stock $305.00
YoY Change -82.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.04M
YoY Change
Total Liabilities & Shareholders Equity $13.58M
YoY Change 131.34%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$3.232M
YoY Change -45.95%
Depreciation, Depletion And Amortization $165.4K
YoY Change 6.95%
Cash From Operating Activities -$3.883M
YoY Change -9.48%
INVESTING ACTIVITIES
Capital Expenditures -$140.8K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $140.8K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 13.40M
YoY Change 126.0%
NET CHANGE
Cash From Operating Activities -3.883M
Cash From Investing Activities 140.8K
Cash From Financing Activities 13.40M
Net Change In Cash 9.659M
YoY Change 488.98%
FREE CASH FLOW
Cash From Operating Activities -$3.883M
Capital Expenditures -$140.8K
Free Cash Flow -$3.743M
YoY Change -12.76%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5979054 usd
us-gaap Net Income Loss
NetIncomeLoss
-9413758 usd
CY2024Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52416 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
511556 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
906215 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5199106 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
402152 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1651518 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3000000 usd
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
8806 usd
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
17057 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
225368 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
358085 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1542541 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10225766 usd
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
4436 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
130663 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
135099 usd
CY2024Q3 us-gaap Liabilities
Liabilities
1542541 usd
CY2023Q4 us-gaap Liabilities
Liabilities
10360865 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3044165 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3044165 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
97293 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
97293 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
305 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
10 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
86074004 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-102357201 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-92943443 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
12037563 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-6869429 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13580104 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3491436 usd
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
Cingulate Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address Address Line1
EntityAddressAddressLine1
1901 W. 47th Place
dei Entity Address City Or Town
EntityAddressCityOrTown
Kansas City
dei Entity Address State Or Province
EntityAddressStateOrProvince
KS
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
66205
dei City Area Code
CityAreaCode
(913)
dei Local Phone Number
LocalPhoneNumber
942-2300
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
2247 usd
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
14622 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1301215 usd
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001862150
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
CY2024Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q1 CING Aoci Unrealized Losses On Available For Sale Investments
AociUnrealizedLossesOnAvailableForSaleInvestments
usd
CY2024Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
usd
CY2024Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
usd
CY2024Q3 CING Stock Issued During Period Value Reverse Stock Splits
StockIssuedDuringPeriodValueReverseStockSplits
usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
usd
CY2023Q4 CING Prepaid Dues And Subscriptions
PrepaidDuesAndSubscriptions
usd
CY2024Q3 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
usd
CY2024Q3 us-gaap Interest Payable Current
InterestPayableCurrent
usd
CY2024Q3 us-gaap Accrued Utilities Current
AccruedUtilitiesCurrent
usd
CY2024Q3 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
dei Document Type
DocumentType
10-Q
dei Entity File Number
EntityFileNumber
001-40874
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-3825535
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3212233 shares
dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.0001
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10040149 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
11343611 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
578594 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2066515 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2545965 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
169978 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
366877 usd
CY2024Q3 us-gaap Assets
Assets
13580104 usd
CY2023Q4 us-gaap Assets
Assets
3491436 usd
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
114394459 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1428504 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3923852 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5116582 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10508395 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1853583 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1825822 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4319902 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5453643 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3282087 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5749674 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-9436484 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-15962038 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
50483 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-229380 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
22726 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-638212 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3231604 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5979054 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9413758 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16600250 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-3231604 usd
us-gaap Net Income Loss
NetIncomeLoss
-16600250 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.83
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.83
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-72.60
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-72.60
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-278.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-278.84
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1766362 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1766362 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82361 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82361 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
936118 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
936118 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59533 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59533 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3882022 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
204479 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4004887 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
81614 usd
CY2023Q2 CING Unrealized Losses On Available For Sale Investments
UnrealizedLossesOnAvailableForSaleInvestments
218798 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
217376 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6616309 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-6098521 usd
CY2023Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
1621939 usd
CY2023Q3 CING Stock Issued During Period Value Issuance Of Common Stock In Connection With Private Placement With Wfia
StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivatePlacementWithWfia
1000000 usd
CY2023Q3 CING Stock Issued During Period Value Sold For Cash
StockIssuedDuringPeriodValueSoldForCash
3310551 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
3949765 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
1862735 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
236251 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5979054 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-96334 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-6869429 usd
CY2024Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
3115284 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6432892 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2734739 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
586511 usd
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
24024 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
164575 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2972477 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
3216119 usd
CY2024Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
1110002 usd
CY2024Q2 CING Stock Issued Value Warrant Inducement
StockIssuedValueWarrantInducement
1614563 usd
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
98434 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
254331 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3209677 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
3083772 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
3083772 usd
CY2024Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
11791624 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
393771 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-3231604 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
12037563 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
12037563 usd
us-gaap Net Income Loss
NetIncomeLoss
-9413758 usd
us-gaap Net Income Loss
NetIncomeLoss
-16600250 usd
us-gaap Depreciation
Depreciation
492788 usd
us-gaap Depreciation
Depreciation
410593 usd
us-gaap Share Based Compensation
ShareBasedCompensation
935135 usd
us-gaap Share Based Compensation
ShareBasedCompensation
658106 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-12375 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-228596 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
789659 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1368658 usd
CING Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-196899 usd
CING Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-194125 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5542256 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1517952 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-132718 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
13428 usd
CING Increase Decrease In Longterm Portion Of Operating Lease Liability
IncreaseDecreaseInLongtermPortionOfOperatingLeaseLiability
-130663 usd
CING Increase Decrease In Longterm Portion Of Operating Lease Liability
IncreaseDecreaseInLongtermPortionOfOperatingLeaseLiability
-263380 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14371857 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12472172 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13338 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
37136 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13338 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-37136 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
24385615 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6151288 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
3000000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
12687 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
11943 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24372928 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9139345 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9987733 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3369963 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
52416 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5356276 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10040149 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1986313 usd
us-gaap Interest Paid Net
InterestPaidNet
6160 usd
us-gaap Interest Paid Net
InterestPaidNet
10266 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10000000.0 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-102400000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zcqzujTQpKE8" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c) <span id="xdx_86A_zIArniotH4v8">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains cash equivalent deposits, which at various times throughout the fiscal year exceeded the amounts insured by the Federal Deposit Insurance Corporation limit of $<span id="xdx_90D_eus-gaap--TimeDepositsAtOrAboveFDICInsuranceLimit_iI_c20240930_zXtwYcBr8VN8">250,000 </span>(without regard to reconciling items). Management monitors the soundness of these financial institutions and does not believe the Company is subject to any material credit risk relative to the uninsured portion of the deposits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Time Deposits At Or Above Fdic Insurance Limit
TimeDepositsAtOrAboveFDICInsuranceLimit
250000 usd
CY2024Q3 CING Prepaid Research And Development
PrepaidResearchAndDevelopment
1088696 usd
CY2023Q4 CING Prepaid Research And Development
PrepaidResearchAndDevelopment
183452 usd
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
128941 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
31302 usd
CY2024Q3 CING Prepaid Active Pharmaceutical Ingredients
PrepaidActivePharmaceuticalIngredients
29025 usd
CY2023Q4 CING Prepaid Active Pharmaceutical Ingredients
PrepaidActivePharmaceuticalIngredients
97324 usd
CY2024Q3 CING Prepaid Dues And Subscriptions
PrepaidDuesAndSubscriptions
20092 usd
CY2024Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
13763 usd
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
178780 usd
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
20698 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
20698 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1301215 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
511556 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5202286 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5188948 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3135771 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2642983 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2066515 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2545965 usd
us-gaap Depreciation
Depreciation
492788 usd
us-gaap Depreciation
Depreciation
410593 usd
CY2024Q3 us-gaap Depreciation
Depreciation
165406 usd
CY2023Q3 us-gaap Depreciation
Depreciation
154663 usd
CY2024Q3 CING Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
202741 usd
CY2023Q4 CING Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
155220 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
91961 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
213922 usd
CY2024Q3 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
80000 usd
CY2023Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
120570 usd
CY2023Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
593022 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
290000 usd
CY2023Q4 us-gaap Accrued Utilities Current
AccruedUtilitiesCurrent
155800 usd
CY2023Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
56088 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
27450 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
66896 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
402152 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1651518 usd
us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<p id="xdx_806_eus-gaap--LossContingencyDisclosures_zAbWHDxnInS7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(6) <span id="xdx_828_zlV9xczmfUEe">Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may, from time to time, be subject to legal proceedings and claims arising in the ordinary course of business and otherwise. A substantial legal liability against us could have an adverse effect on our business, financial condition and results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records legal costs associated with loss contingencies as incurred and establishes reserves when those matters present material loss contingencies that management determines to be both probable and reasonably estimable in accordance with ASC 450, <i>Contingencies. </i>If a range of loss is estimated, and some amount within that range appears to be a better estimate than any other amount within that range, then that amount is accrued. If no amount within the range can be identified as a better estimate than any other amount, we accrue the minimum amount in the range. These amounts are not reduced by amounts that may be recovered under insurance or claims against third parties, but undiscounted receivables from insurers or other third parties may be accrued separately if recovery is considered probable. Management’s judgment is required related to loss contingencies because the outcomes are difficult to predict, and the ultimate resolution may differ from our current analysis. The Company revises accruals in light of new information. While it is not possible to predict the outcome of loss contingencies with certainty, management is of the opinion that adequate provision for potential losses associated with any such matters has been made in the financial statements. No accruals for loss contingencies were recorded in the consolidated balance sheets as of September 30, 2024 or 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
3000000.0 usd
CY2023Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
8000000.0 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3044165 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3044165 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
97293 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
97293 shares
CY2023Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-twenty
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-twelve reverse stock split
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Debt Instrument Description
DebtInstrumentDescription
The holders of pre-funded warrants may not exercise the warrants if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the number of shares of common stock outstanding immediately after giving effect to such exercise. Each share of common stock and each pre-funded warrant were sold along with one Series A and 0.5 Series B warrants
CY2024Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
7500000 usd
CY2024Q1 us-gaap Payments For Fees
PaymentsForFees
750950 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0426 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y5M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.0146 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.04
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.04
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
91.80
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
10378126 usd
CY2024Q3 CING Equity Fair Value Percentage
EquityFairValuePercentage
1.0000 pure
CING Amount Allocated
AmountAllocated
7500000 usd
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
833684 shares
CY2024Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
33708854 usd
CY2024Q3 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-678639 usd
CY2023Q3 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1255601 usd
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1976891 usd
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3486052 usd
CY2024Q3 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-233562 usd
CY2023Q3 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-330642 usd
us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-579614 usd
us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-917994 usd
CY2024Q3 CING Income Tax Reconciliation Permanent Difference
IncomeTaxReconciliationPermanentDifference
3233 usd
CY2023Q3 CING Income Tax Reconciliation Permanent Difference
IncomeTaxReconciliationPermanentDifference
6154 usd
CING Income Tax Reconciliation Permanent Difference
IncomeTaxReconciliationPermanentDifference
9307 usd
CING Income Tax Reconciliation Permanent Difference
IncomeTaxReconciliationPermanentDifference
14457 usd
CY2024Q3 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1832122 usd
CY2023Q3 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2218188 usd
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3500000 usd
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
5089875 usd
CY2024Q3 CING Income Tax Reconciliation Research And Development Tax Credits
IncomeTaxReconciliationResearchAndDevelopmentTaxCredits
972372 usd
CY2023Q3 CING Income Tax Reconciliation Research And Development Tax Credits
IncomeTaxReconciliationResearchAndDevelopmentTaxCredits
620630 usd
CING Income Tax Reconciliation Research And Development Tax Credits
IncomeTaxReconciliationResearchAndDevelopmentTaxCredits
972372 usd
CING Income Tax Reconciliation Research And Development Tax Credits
IncomeTaxReconciliationResearchAndDevelopmentTaxCredits
620630 usd
CY2024Q3 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
49218 usd
CY2023Q3 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-17469 usd
us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
19570 usd
us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-79656 usd
CY2024Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
16121058 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
12631033 usd
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001493152-24-043916-index-headers.html Edgar Link pending
0001493152-24-043916-index.html Edgar Link pending
0001493152-24-043916.txt Edgar Link pending
0001493152-24-043916-xbrl.zip Edgar Link pending
cing-20240930.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
cing-20240930_def.xml Edgar Link unprocessable
cing-20240930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cing-20240930_cal.xml Edgar Link unprocessable
cing-20240930_pre.xml Edgar Link unprocessable